Patients should be counseled on hypoglycemia recognition and management, particularly those receiving concurrent medications that affect blood glucose
Report any suspected side effects to the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
Diet quality and protein intake This is arguably the single most important modifiable factor in determining GLP-1 results
Cuthbertson DJ, Irwin A, Gardner CJ et al (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists
Drug manufacturers oppose the move, warning it creates a loophole around the years of clinical trials normally required to approve a medication
What Research Shows (Up to 12 Weeks): Chronic toxicity : None documented (studies up to 12 weeks) Organ damage : None detected in histopathological examination Carcinogenic effects : None observed (though dedicated cancer studies haven't been done) Reproductive toxicity : None found in limited fertility studies What We Don't Know: 1
